Karma validates volumetric breast density measurement tool

KARMA is the first study validating the performance of a volumetric breast density software (VolparaDensity) in a large-scale setting. Results of the study show that distributions of volumetric density are similar across different vendor platforms and that Volpara breast density is associated with established density determinants and breast cancer risk. Link to published article: Cancer…


Karma plans a randomized clinical trial to investigate the effect of different doses of Tamoxifen through measuring the decrease of breast density in healthy women.

Tamoxifen has been used for several years as adjuvant therapy for women diagnosed with breast cancer. Tamoxifen was introduced already in the 1970s and reduces the risk of breast cancer recurrence with approximately 30%. Recent studies also indicate that use of Tamoxifen as primary prevention for healthy women at high risk reduce breast cancer incidence….


Karma launch clinical trial for breast cancer detection with new techniques.

Karma Kamera is the study name of a clinical trial at Södersjukhuset, Stockholm, introducing a new technique developed by Real Imaging ( Real Imaging’s 3D Functional Metabolic Imaging and Risk Assessment (MIRA) technology is intended to provide a non-invasive non-radiation, and examinee-friendly procedure to determine breast health through the acquisition and analysis of 3D metabolic…


Breast cancer researcher connected to Karma wins L’Oreal women’s science fellowship

Dr Li Jingmei, 31, received this year’s UNESCO-L’Oreal International For Women In Science Fellowship, one of 15 women scientists around the world to do so. Li Jingmei currently work as postdoctoral research fellow at the Agency for Science, Technology and Research’s Genome Institute of Singapore, but have strong connections to Karolinska Institutet and the Karma-group She…


Study shows mammographic density reduction as a prognostic marker of improved survival

Mammographic Density Reduction Is a Prognostic Marker of Response to Adjuvant Tamoxifen Therapy in Postmenopausal Patients With Breast Cancer Tamoxifen treatment is associated with a reduction in mammographic density and an improved survival. However, the extent to which change in mammographic density during adjuvant tamoxifen therapy can be used to measure response to treatment is…


70,000 participants in Karma

The Karma study today passes 70,000 participants which makes the study the largest and most well-characterized breast cancer study worldwide.


Unique study reveals genetic spelling mistakes that increase the risk of common cancers

[Press release, 27 March 2013] More than 80 genetic ’spelling mistakes’ that can increase the risk of breast, prostate and ovarian cancer have been found in a large, international research study within the framework of the EU Network COGS. For the first time, the researchers also have a relatively clear picture of the total number of genetic alterations that can…


Launching Karma Normal to study mammographic density in healthy women

In a substudy to Karma, scientists will study why it is more common among women with high mammographic density to develop breast cancer. The study will investigate breast tissue biopsies from women with low breast density and compare this with biopsies from women with dense breasts. Karma Normal is a collaboration between researchers at the…


50,000 women participates in the Karma study

Breast cancer has steadily increased over the past 40 years. In Sweden, one woman per hour is diagnosed with breast cancer and every six hours a woman dies from the disease. The need to prevent the onset of breast cancer is high. Therefore researchers at the Karolinska Institute in collaboration with four hospitals in Sweden…


High-throughput mammographic density measurement: a tool for risk prediction of breast cancer

Mammographic density (MD) is a strong, independent risk factor of breast cancer, but measuring MD is time-consuming and reader-dependent. Objective MD measurement in a high-throughput fashion would enable its wider use as a biomarker for breast cancer. We use a public domain image processing software for the fully automated analysis of MD and penalised regression…


Karma in Nobel conference on breast cancer

Leading breast cancer researchers meet in Stockholm on the 59th Nobel Conference to exchange knowledge on the rapidly growing breast cancer worldwide and to start new research projects. Read more


The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

The elucidation of breast cancer subgroups and their molecular drivers requires integrated views of the genome and transcriptome from representative numbers of patients. We present an integrated analysis of copy number and gene expression in a discovery and validation set of 997 and 995 primary breast tumours, respectively, with long-term clinical follow-up. Inherited variants (copy…


Dr Hall at Athena Breast Health Forum

Dr Hall is invited to San Francisco to participate in Athena Breast Health Forum.  A serie of discussions about outstanding questions and advancements in breast health between breast cancer experts, health care providers, patients and community members. Athena Breast Health Forum


19p13.1 is a triple negative-specific breast cancer susceptibility locus

The 19p13.1 breast cancer susceptibility locus is a modifier of breast cancer risk in BRCA1 mutation carriers and is also associated with risk of ovarian cancer. Here we investigated 19p13.1 variation and risk of breast cancer subtypes, defined by estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status, using 48,869…


Karma has opened its 4th unit

Karma’s 4th sampling unit is situated in Lund. “Without Unilabs Skåne’s cooperation this had never been possible”, says Per Hall and continues “The Karma study is now recruiting almost a thousand women a week, which is a stunning figure”.


Genome-wide association analysis identifies three new breast cancer susceptibility loci

Breast cancer is the most common cancer among women. To date, 22 common breast cancer susceptibility loci have been identified accounting for ∼8% of the heritability of the disease. We attempted to replicate 72 promising associations from two independent genome-wide association studies (GWAS) in ∼70,000 cases and ∼68,000 controls from 41 case-control studies and 9…


New model for data export

We are proud to present the Karma Research Platform (beta) that we believe will become a game-changer for breast cancer prevention research.


20 000 unique participants

The Karma study, which started in Helsingborg on January 11th 2011, has within eleven months recruited more than 20 000 participants


Karma Research Platform (beta) up and running.

The Karma Research Platform (beta) is now up and running. As of today, any scientist with sound science can get access to the world’s best-characterized breast cancer cohort. “We are proud to present the Karma Research Platform. With more than 20,000 participants and a steady inflow of more than 800 women per week I believe…


Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start blogging!